Semax vs. Selank Two Russian-Approved Peptides and What Western Researchers Can Learn From Their Trial Data
Suppose the most significant advances in cognitive therapy and anxiety therapy have already been written up, not in the pages of Nature, but in decades-old Russian clinical archives the Western research community has been virtually ignoring.
It is not a conspiracy theory. It is a knowledge gap, and it is becoming smaller.
Two neuropeptide analogs of Semax and Selank are pharmaceutical drugs in Russia developed decades ago at the Institute of Molecular Genetics of the Russian Academy of Sciences. They contain a lot of clinical and preclinical information.
In North America and Western Europe, however, they are virtually unknown to the mainstream researchers. To the open-minded who are not biased by institutional dogma, the trial data on these two compounds provide some of the most practical information in neuropeptide science at present.
Born from the Same Lab, Built for Different Battles
Both Semax and Selank have a common origin: the same research program of the Soviet era in Moscow. Unlike simple peptides when they are used as single-target agents, the compounds are designed in an exceptionally pharmacologically precise manner.
The Semax is an artificial heptapeptide analog of the ACTH (4–10) peptide fragment. It is named after the Russian word “semax,” meaning seven, and hence “amino acids.” Scientists cloned a particular part of the naturally existing adrenocorticotropic hormone and attached a stabilizing tail of pro-Gly-Pro. which could extend the half-life of the peptide up to 20-24 hours instead of just less than an hour. This was methodically engineered to strip ACTH of its hormonal effects, and its cognitive properties and neuroprotective properties were retained and enhanced.
In Russia, Semax was approved on prescription in 1996 and is currently listed as one of the vital and essential drugs in the state. Selank had another pathway of development. It was based on tuftsin, which is a natural immunomodulatory tetrapeptide generated by the spleen.
The Pro-Gly-Pro extension has also been done similarly to increase its bioavailability and action span tremendously. In 2009, Russia registered Selank to treat generalized anxiety disorder (GAD) and neurasthenia, diseases that affect hundreds of millions of people in the world and for which there are no historical drugs. In case Semax acts like a cognitive accelerator, the stabilizer of the neurology is Selank.
What the Trial Data Actually Reveals
Semax has proven to have clinically meaningful results on the topic of cognition and neuroprotection. It was reported in a trial of stroke patients that the Semax supplement to usual care substantially increased plasma BDNF (brain-derived neurotrophic factor) levels, and patients whose BDNF levels were higher exhibited a significantly better rehabilitation course.
Semax Intranasal Semax stimulated attention and short-term memory in healthy volunteers at a dosage of 250–1,000 mcg/kg, with EEG activity similar to known neuroprotective drugs. Up to 24 hours, there were also cognitive effects with a single intranasal dose, which is an extraordinary duration of action for any nootropic agent.
At the mechanistic level, Semax stimulates BDNF and TrkB receptor expression in the hippocampus within a short time. It also affects the serotonin and dopamine systems, and that explains the reported gain in attention, mood stability, and resistance to stress.
Interestingly, its serotonergic activity has also been linked to sleep architecture changes, a domain more commonly associated with the delta sleep-inducing peptide, which acts on slow-wave sleep regulation. Although the Semax does not present those sleep-specific effects, the serotonergic modulation overlap suggests that these have a common neurochemical substrate to be studied.
The Safety Profile: Underreported and Undervalued
Both compounds have proven to be very tolerable in clinical practices. Combined with intranasal administration, over a duration of not more than 30 days, studies noted very few adverse effects, and no toxicity was reported. Semax is variously linked with slight nasal allergy, temporary headache with high dosages, and slight temporary rise in blood sugar levels in diabetics
The side effects profile of Selank is also mild: momentary nasal irritation, occasional changes in taste, and, rarely, high doses can cause sedation, which is associated with serotonergic changes, and at times, dreams can be vivid.
Both compounds have not been linked to emotional blunting, rebound anxiety, or the emergence of tolerance.
This practical safety record, accredited over the decades of using pharmaceuticals in Russia, is gradually becoming the focus of attention of Western scientists who are starting to appreciate the value of this safety record in evidence-based evaluations of the same peptide therapy as a legitimate therapeutic modality in neuropsychiatry.
Peptide Therapy and the Western Research Gap
The growing evidence surrounding Semax and Selank makes a compelling case for integrating peptide therapy into Western neuropsychiatric research pipelines. The particular actions of these compounds—BDNF up-regulation, GABAergic modulation, and serotonin pathway regulation are exactly the ones that modern neuropsychiatry has been striving to accomplish, but using much more complicated and potentially more dangerous pharmaceutical means.
In order to put this into perspective in the larger terrain of accepted peptide compounds, the West has already urged peptide-based treatment in other areas. The tesamorelin peptide, for instance, is FDA-approved for the reduction of excess abdominal fat in HIV-positive patients, demonstrating that regulatory bodies in the West are capable of evaluating and approving peptide-based interventions when presented with rigorous data. The question is, why had the same rigor not been applied to neuropeptides, which have as good, possibly better, clinical evidence behind them?
The main issue is not that there is no efficacy data. The problem is accessibility. Much of the early literature on Semax and Selank is published in Russian journals, and there is, therefore, an information vacuum so that researchers in the United States and Europe are mostly unaware of the compounds that have already successfully passed through stringent regulatory systems in a different jurisdiction. Any researcher who rejects this body of literature simply because of linguistic or geopolitical reasons is not using scientific rigor; that researcher is using institutional inertia.
Two Peptides, One Clear Lesson
It is not really the tale of two molecules of Semax and Selank. It is concerning what occurs when decades of institutionally approved, scientifically extensive, clinical research are dismissed due to the fact that the results were printed in a different language or by the incorrect organizations.
To Western researchers who are actually willing to stretch their methodological boundaries, the Russian clinical trial data on these compounds represent a rare and largely unexploited treasure trove: practical, peer-reviewed data on neuroprotective and anxiolytic peptides that have already passed through the strictest regulatory checks that their country of origin can impose.
Disclaimer: This article is for informational and educational purposes only. The information presented is based on publicly available research and should not be considered medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before considering any peptide or experimental compound.
